Key words
Ginkgo biloba
- Ginkgoaceae - neurodegeneration - retinal diseases - age-related macular degeneration
- diabetic retinopathy - glaucoma - ischaemic retinal disease
Abbreviations
ARMD:
age-related macular degeneration
BD:
Behcetʼs disease
CNV:
choroidal neovascularisation
DR:
diabetic retinopathy
GBEs:
Ginkgo biloba extracts
IOP:
intraocular pressure
NO:
nitric oxide
NOX:
NADPH oxidase
NTG:
normal-tension glaucoma
PAF:
platelet activating factor
POAG:
primary open-angle glaucoma
PUFAs:
polyunsaturated fatty acids
RCTs:
randomised controlled trials
RD:
retinal detachment
ROMs:
reactive oxygen metabolites
ROS:
reactive oxygen species
RP:
retinitis pigmentosa
RPE:
retinal pigment epithelium
TM:
trabecular meshwork
VEGF:
vascular endothelial growth factor
Introduction
The degeneration of retinal ganglion cells is involved in several optic neuropathies.
These cells are neuronal retinal cells that project their axons to the brain by forming
the optic nerve [1 ]. The long axons of these cells make them more vulnerable to hypoxia, exposure to
free radicals, mechanical compression, and photo-oxidative damage [2 ]. Some retinal diseases are directly related to oxidative stress, especially in aging
eyes [3 ]. Like other neuronal cells, retinal ganglion cells have poor antioxidant capacities
and insufficient nucleic acid repair mechanisms (mainly in mitochondria) [4 ]. ROS are involved in the progression of retina disorders, including aging, apoptosis,
and post-ischaemic cellular injuries [5 ]. Glaucoma [6 ], [7 ], DR [8 ], [9 ], [10 ], ARMD [11 ], [12 ], and ischaemic retinal injuries [13 ] are examples of ROS and retina disease relationships. In addition, excessive ROS
generation and the consequent induction of oxidative stress are some factors that
trigger the cellular response to RD, and are also a major cytotoxic factor for photoreceptor
apoptosis [14 ]. Indeed, antioxidants protect against oxidative stress and prevent ROS production,
and they should act as neuroprotectants with therapeutic options for retinal diseases.
Ginkgo biloba L. (Ginkgoaceae), commonly known as ginkgo, is a living fossil, as it is one of the
most ancient living trees that has existed for more than 250 million years. The therapeutic
benefits of ginkgo leaf extracts have long since been well known, proven by the fact
that they were used in traditional Chinese medicine 5000 years ago [15 ]. Dr. Willmar Schwabe introduced ginkgo leaf extract as medication in 1965 [16 ]. Many types of GBEs can be found on the market nowadays, but preclinical and clinical
studies have been performed mainly using EGb 761 and LI 1370 [17 ], especially the former. EGb 761 is one of the best characterised herbal extracts,
containing two major groups of active principles, flavonoids (24%) and terpene lactones
(6%). Quercetin, kaempferol, iso-rhamnetin, myricetin, laricitrin, mearnsetin, and
apigenin glycosides have been identified as the main flavonoids, together with biflavonoids
like ginkgetin and isoginkgetin [18 ]. Ginkgolides A, B, C, and J (diterpene lactones) and bilobalide (sesquiterpene lactones)
are the most important components of the terpene fraction [19 ]. Another important aspect of this extract is that ginkgolic acids appear in concentrations
below 0.0005%. Ginkgolic acids exert allergenic and genotoxic effects, with neurotoxic
results. It has been proven that ginkgolic acid-induced death is mediated by both
apoptosis and necrosis [20 ]. In fact, due to low concentrations of this type of compounds in EGb 761, toxic
effects in humans are not expected. EGb 761 and other ginkgo leaf extracts have been
widely used to treat and prevent several disorders like Alzheimerʼs disease, dementia,
multiple sclerosis, asthma, vertigo, fatigue, tinnitus, and circulatory problems [21 ], [22 ], [23 ]. The neuroprotective effect of this plant has been demonstrated both in vitro and in vivo . The terpenoid and flavonoid fractions of GBEs protect neurons against necrosis and
apoptosis induced by ROS, Ca2+ overload, NO, and β -amyloid-induced toxicity [16 ]. The antioxidant capacity of the extract can be explained by its ability to act
as a free radical scavenger of nearly all ROS types, and can inhibit lipid peroxidation.
Furthermore, antioxidant properties of ginkgo are particularly interesting given the
ability of its active principles, mainly the flavonoid fraction, to act at the mitochondrial
level, unlike other antioxidants [17 ]. GBEs maintain ATP content thanks to mitochondrial respiration protection and oxidative
phosphorylation preservation. The neuroprotective capacity of ginkgo leaves should
allow for the treatment and prevention of ocular pathologies such as glaucoma, DR,
and ARMD [2 ]. The vasoregulator effects of ginkgo through the catecholaminergic system and the
release of endothelial factors, and its capacity to increase microcirculation [24 ], are also interesting points for this propose [25 ]. Finally, GBEs seem safe and well tolerated, as adverse reactions to ginkgo treatment
are rare and mild [26 ].
This review concentrates on the therapeutic potential of ginkgo to treat retinal diseases
associated with neurodegeneration. In particular, it focuses on damage caused by oxidative
processes: ARMD, DR, glaucoma, ischaemic retinal disease, retinal disease produced
by light oxidation, and RD, among other diseases. The aim of the current review is
to integrate information of the possible ways to protect and the therapeutic role
of GBEs. The search strategy was conducted using a systematic and standardised review
of curated databases such as PubMed, MEDLINE, and SciFinder in 2000 – 2019. Papers
published in 1985 – 2000 were used when they were necessary to explain concepts and
processes. The search was based on the following key words: Ginkgo biloba , Ginkgoaceae, neurodegeneration, retinal diseases, age-related macular degeneration,
diabetic retinopathy, glaucoma, and ischaemic retinal disease. Other key words were
used for secondary search (oxidative processes, neurodegenerative disease, antioxidant
substances).
Age-Related Macular Degeneration
Age-Related Macular Degeneration
ARMD is a multifactorial neurodegenerative ocular disease characterised by progressive
macula lesions that result in irreversible central vision loss [27 ], [28 ], [29 ]. The macula, a small portion of the central area of the retina containing the maximum
density of photoreceptors, is the part of the eye that provides sharp central vision,
and is responsible for the most detailed vision that we need for objects that lie
straight ahead. Currently, it represents the leading cause of visual impairment and
acquired irreversible blindness in people aged over 60 years in developed countries.
ARMD has a high prevalence worldwide. More than 170 million people suffer from ARMD
worldwide and this number is expected to rise because of aging populations. Thus,
the overall prevalence of advanced ARMD is estimated to increase by more than 50%
by the year 2020 [29 ], [30 ], [31 ], [32 ]. ARMD often produces very few symptoms in its early stages, but in later stages,
it causes loss of the central, straight-ahead vision needed for activities like reading
and driving. According to a classification system defined in the National Eye Instituteʼs
Age-Related Eye Disease Study (ARED) [29 ], ARMD can be categorised into three disease progression stages. People with early
ARMD do not normally suffer from vision loss. Intermediate ARMD may cause some vision
loss, but most people will not experience any symptoms. People with late ARMD suffer
vision loss from a damaged macula. Late ARMD is classified into two general subgroups:
dry ARMD and wet ARMD. Dry (atrophic, non-exudative) ARMD is characterised by drusen
accumulating around the RPE with a gradual breakdown of not only the light-sensitive
cells in the macula that convey visual information to the brain, but also of the supporting
tissue beneath the macula. These changes cause vision loss, leading to a choroid and
retinal atrophy (geographic atrophy). In wet (neovascular or exudative) ARMD, abnormal
blood vessels grow underneath the retina. These vessels can leak fluid and blood,
which may lead to the macula swelling and to damage. Such damage may be rapid and
severe, unlike the more gradual course of dry ARMD. Approximately 85 – 90% of macular
degeneration cases are the dry type, while the wet type represents 10 – 15% of the
overall prevalence [29 ], [33 ]. Several risk factors for ARMD to develop and progress have been established, including
aging, genetic factors, smoking, nutrition, degree of pigmentation, arterial hypertension,
and UV rays [27 ], [30 ], [34 ]. Despite its pathogenesis remaining obscure, different studies provide consistent
evidence to suggest a crucial role for retinal pigment epithelial cell damage and
death behind the causes of ARMD. Although the underlying mechanisms of retinal degeneration
are not fully understood, inflammation and oxidative stress responses are involved
as central players in photoreceptor death and vision loss [12 ], [35 ], [36 ]. The abundance of PUFAs in the retina, which are selective substrates for peroxidation,
along with ROS generation cause damage to photoreceptors and RPE via the lipid peroxidation
process [37 ]. Moreover, aging cells are particularly vulnerable because the natural antioxidant
capacity decreases and the overall efficiency of reparative systems against cell damage
become impaired. Several research works report that excessive N -retinylidene-N -retinylethanolamine (A2E) accumulation in the RPE is implicated in the pathogenesis
of ARMD [38 ]. There is also compelling evidence to indicate the association of VEGF to CNV processes
in wet ARMD [28 ], [39 ]. Although currently available treatments can slow down the vision loss rate in neovascular
ARMD, they do not significantly improve vision. Presently, the therapeutic mainstays
used to treat wet ARMD include verteporfin (Visudyne) photodynamic therapy and intravitreal
anti-VEGF agents [28 ], [33 ]. Despite the advances made in understanding ARMD and the recent introduction of
new treatments for some forms of ARMD, these new intravitreal applications of anti-VEGF
are not able to reverse the central visual loss due to the disease, and presently
there is no available treatments for the majority of affected people [28 ], [30 ], [33 ], [40 ], [41 ]. With the limited treatment options available, and given the relatively high prevalence
and increased incidences of ARMD as populations age, several studies have explored
the potential benefits of nutrients and other supplements that can delay disease progression
to minimise visual loss [42 ], [43 ], [44 ], [45 ]. Oxidative stress is considered a crucial event for retinal tissue damage and is
implicated as a contributing factor in the pathogenesis of ARMD. Consequently, experimental
and clinical studies have investigated the use of antioxidants and other micronutrient
supplements as potential strategies to delay the progression of ARMD and visual loss
[35 ], [36 ], [46 ], [47 ]. Thus, the potential protective properties of antioxidant and anti-inflammatory
medicinal plants and phytochemicals on degenerative ocular diseases have been investigated
[48 ], [49 ], [50 ]. The main herbal medicines recommended to treat ARMD include xanthophylls lutein,
zeaxanthin, and ginkgo [42 ], [48 ], [51 ], [52 ]. The literature also describes the photo-protective effect of berries [bilberry
(Vaccinium myrtillus L.), cranberry (Vaccinium oxycoccos L.), blackcurrant (Ribes nigrum L.), wolfberry (Lycium barbarum L.), grapes (Vitis vinifera L.)], stigmas [such as saffron (Crocus sativus L.)], and roots and rhizomes [such as turmeric (Curcuma longa L.) and Dan Shen (Salvia miltiorrhiza Bunge) [36 ], [48 ], [50 ], [53 ], [54 ], [55 ], [56 ], [57 ], [58 ], [59 ] on age-related ocular diseases. Ginkgo has become an increasingly well-known medicinal
plant worldwide, and is used to treat peripheral vascular disease and cerebral insufficiency
[16 ], [22 ], [23 ], [24 ]. Experimental and clinical studies have revealed the potential benefits of ginkgo
for a wide range of pathological conditions, including hepatoprotective, photoprotective
effects, DNA repair mechanism, and antioxidant and anti-inflammatory activities [11 ], [12 ], [19 ], [60 ], [61 ], [62 ], [63 ]. It has been reported that ginkgo effects are related to its free radical quenching
properties, reduction of platelet aggregation, and improved blood flow, mainly due
to the antioxidant and radical scavenging properties of ginkgo flavonoids and terpenoids,
and to the potent and selective PAF antagonism of ginkgolides [48 ], [50 ], [58 ], [61 ]. Flavonoids seem to prevent or reduce cell membrane lipid peroxidation and reduce
damage to lipid membranes [61 ], [62 ], [63 ]. Different in vitro and in vivo experimental studies have shown that EGb 761 can inhibit or reduce functional retinal
impairments and protect retinal tissue from oxidative stress [11 ], [64 ], [65 ], [66 ]. The EGb 761 effect on retinal microcirculation has also been demonstrated, with
increased microcircular blood velocity, flow, and volume [67 ]. Consequently, the use of ginkgo extracts in treating patients with age macular
degeneration has aroused emerging interest because vascular factors and oxidative
damage are thought to be two potential mechanisms in the pathology of ARMD [43 ], [63 ]. Ginkgo extracts also have minimal adverse effects within the daily dose range [26 ], [52 ], [61 ]. It should be noted, however, that there is some concern about ginkgo extract possibly
increasing the risk of bleeding because one of its components, ginkgolide B, is a
potent PAF inhibitor. The literature reports only one case in which regular ginkgo
use is associated with vitreous haemorrhage in a 78-year-old woman with ARMD [68 ]. Recently, several preliminary studies have investigated the efficacy of GBEs in
patients. The literature includes a systematic review published in 2013 [52 ] that reports two RCTs using GBEs with positive effects on vision in patients with
ARMD. In the Lebuisson et al. RCT [69 ], a double-blind trial was conducted to compare EGb761 (80 mg twice daily, 160 mg)
with a placebo in 10 outpatients aged over 55 years attending an eye clinic. Treatment
lasted for 6 months. Drug effectiveness was assessed on fundoscopy results and on
visual acuity and visual field measurements. Despite the small population sample,
a statistically significant improvement in long-distance visual acuity was observed.
In a controlled double-blind trial with 99 patients aged 59 years or more, Fies and
Dienel [70 ] compared the therapeutic efficacy of EGb 761 over a 6-month treatment period with
either 240 mg/day (group I: 50 patients) or 60 mg/day (group II: 49 patients). The
study participantsʼ vision markedly improved in both treatment groups only after 4
weeks, with more pronounced improvements in group I. According to Evans [52 ] and Sin et al. [59 ], both RCTs showed positive effects of ginkgo on vision, but these trials were too
small with a short observation period to provide concluding evidence. In addition,
Bartlett and Eperjesi [42 ] suggested that Lebuissonʼs beneficial findings should be viewed cautiously as the
assessment of the outcome was not masked. Dubey et al. [63 ] considered that the question as to whether ARMD patients should take EGb 761 has
not yet been fully answered and further studies to establish the efficacy of ginkgo
are required. To conclude, although there are many positive outcomes for preventive,
or even therapeutic, uses of GBEs for ARMD, its efficacy remains controversial and
there is still no compelling scientific evidence. Further research into the potential
clinical role should be conducted.
Retinal Detachment
RD is a serious event that can result in vision loss. Retinal photoreceptors receive
oxygen and metabolic support from the choroid. If the retina separates from the choroid,
photoreceptor cells die and cause damage that can lead to blindness. Basically, there
are three types of RD, the most frequent being rhegmatogenous (RRD) that develops
due to retinal rupture and by fluid passing from the vitreous cavity to the potential
space below the retina, which leads to the retina separating from the underlying choroid.
This requires surgical treatment [71 ]. Although RD can appear in any eye, certain eyes are predisposed to develop it,
and the risk factors to be considered are axial myopia, post-cataract surgery, ocular
trauma, RD in an eye, family history of RD, and various retinal disorders, including
ARMD [72 ] and DR [73 ], among others. Despite the high prevalence of these conditions, there are currently
few or no treatments available. Retinal treatment is successful in 80 – 99% of cases,
but retinal death due to RD has no treatment. Therefore, preventive intervention may
be the most effective course of action against these age-related eye diseases. It
should be noted that all these retina diseases are associated with aging and their
aetiology shares some mechanisms of action. These pathways include oxidative stress,
inflammation, and apoptotic factors, which provide information on potentially targetable
areas [74 ]. Currently, one of the therapeutic approaches does not focus so much on the causes
of diseases, but on ways to prevent cell death, such as administration of antiapoptotic,
anti-inflammatory, or neurotrophic compounds. In fact, the use of antioxidant compounds
or antiapoptotic, anti-inflammatory, or viability factors can slow down retina neurodegeneration
by delaying retinal cell death [75 ]. In recent years, many epidemiological and clinical studies have been conducted
and demonstrated the beneficial effects of plant-derived compounds in eye diseases.
Many natural compounds exhibit strong antioxidant, anti-inflammatory, and antiapoptotic
properties, such as flavonoids and terpenes, which are the main active ingredients
in ginkgo leaves. In fact, GBEs have relevant properties, such as protection against
free radical damage and lipid peroxidation [48 ], [50 ], [59 ], [61 ], [62 ], [63 ], [74 ]. Marcocci et al. [76 ] pointed out the protective capacity that GBEs show against NO in studies on mammalian
cells. By preventing the loss of ganglion cells in the retina and optic nerve atrophy,
these GBE properties can protect the optic nerve from degeneration and, thus, prevent
blindness in patients with glaucoma, RD, and RP [77 ]. Ma et al. [78 ] conducted studies with Sprague-Dawley rats by injecting a GBE, followed by the crushing
of the optic nerve. The animals that received the GBE by intraperitoneal injection
prior to the optic nerve crushing showed a significantly higher survival rate of ganglion
cells in the retina than the controls. Since the development of EGb 761 in the 1960s
[79 ], this extract has been the most widely studied extract in clinical research, whose
effect has been investigated in a wide range of disorders and diseases. Numerous studies
show that EGb 761 is a relevant antioxidant extract that can provide effective protection
against oxidative stress [80 ], [81 ]. Therefore, EGb 761 has powerful properties to eliminate free radicals and offers
protection against oxidative stress. The therapeutic potential of EGb 761 can, at
least in part, be attributed to this antioxidant action. In another study with an
experimental model of tractional RD, Baudouin et al. [82 ] confirmed the efficacy of EGb 761 to prevent retinal retraction. These authors investigated
the effects of this extract administered orally for 1 month after inducing vitreoretinopathy.
The untreated animals developed an inflammatory reaction, and extensive intravitreal
and preretinal membranes, which led to tractional RD. In treated animals, EGb 761
prevented the inflammatory reaction, reduced vitreoretinal proliferation, and decreased
the frequency of RD. Studies conducted with Kunming mice showed that EGb 761 inhibits
the apoptosis of photoreceptor cells and increases cell survival after damaging or
intense light exposure [83 ]. EGb761 has also been indicated to prevent RD-related inflammation after inducing
vitreoretinopathy and, thus, reduced the occurrence of RD [77 ]. Paasche et al. [84 ] studied age-related changes of mitochondria in Müller (retinal glial) cells from
guinea pigs fed with, or not, externally applied EGb 761, an established radical scavenger.
The obtained results suggested that many structural and functional parameters of the
mitochondrial aging of Müller cells were affected by oxidative damage, and that externally
applied radical scavengers could protect organelles from the damaging actions of free
radicals. Treatment with EGb 761 increased the intrinsic glutathione content of aged
guinea pig Müller cells, and the protective effect of the radical elimination of the
drug was mediated both directly and indirectly. In the article “Neuroprotection for
Retinal Detachment”, Huckfeldt and Vavvas [85 ] reviewed the main pathways of cell death activated by RD and progress in the development
of neuroprotective strategies. They pointed out that, although current results are
promising, functional aspects in the clinical setting have not yet been tested. The
physiological responses observed after RD are complicated, and effective neuroprotection
may require a combinatorial approach, such as surgical treatment and complementary
drug therapy, to address inflammatory and proliferative causal responses. Similarly,
Murakami et al. [86 ] conducted a study on photoreceptor cell death and RD, and considered that a better
understanding of the molecular mechanisms related to the death of these cells would
allow new therapies to be developed to prevent vision deficits due to loss of photoreceptor
cells. According to Li et al. [87 ], currently, no effective therapy is clinically available to protect photoreceptor
cells. Therefore, the development of neuroprotective reagents for photoreceptors could
contribute to long-term visual stability for postoperative RD patients. These authors
used an experimental RD model and provided evidence that oxidative stress and inflammation
are activated in the retina after RD, and photoreceptors are an important source of
ROS production by regulating NOX. Their results pointed out that adrenergic receptors
were novel therapeutic targets for neuroprotective substances to prevent the death
of photoreceptors induced by RD.
Diabetic Retinopathy
DR is the most common microvascular complication of diabetes mellitus, and one of
the leading causes of blindness worldwide [48 ]. One-third of the worldʼs diabetic population presents different DR stages [88 ]. DR is a complex event; oxidative stress and inflammation are the main pathways
to affect the pathogenesis of DR, which is characterised by neuronal and pericyte
cell loss, the formation of acellular occluded capillaries and microaneurysms that
result in capillary non-perfusion and hypoxia, increased leukostasis, and vascular
basement membrane thickening. These alterations trigger microvascular complications
by leading to the breakdown of the blood-retina barrier, exudates, haemorrhages, and
profound ischaemia of the retina leading to neovascularisation [89 ]. Injuries induced by diabetes and hyperglycaemia are related with increased arginase
activity and low levels of bioavailable NO, and overactive arginase may contribute
to DR by reducing NO and increasing oxidative stress due to arginase activity. Furthermore,
the serum of diabetic patients increases the levels of ROMs compared with healthy
subjects, and it has been demonstrated that ROMs increase rapidly in serum as DR progresses
[89 ]. The main treatment for DR is intensive glycaemic control. Another important treatment
is laser photocoagulation, but it is not effective in many patients. In patients with
diabetic macular oedema, this being the major complication of DR, intravitreal steroid
injections are used (including triamcinolone, which it is not very common nowadays,
and dexamethasone implants, which is more common). The intravitreal administration
of VEGF has been developed in recent years [90 ]. The prevention of the vascular complications of diabetes is now an important public
health priority worldwide. Currently, the treatments associated with antidiabetic
drugs mostly intend to regulate vascular changes, inflammation, and to reduce oxidative
stress. In this context, GBEs have drawn attention, given their antioxidant and platelet
anti-aggregation properties and other effects, such as dilated blood vessels and improved
abnormal blood rheology [89 ], [91 ]. According to recent studies, using ginkgo is a good option to prevent the progress
of DR and to reduce its prevalence. Zhao et al. [91 ] demonstrated that administering ginkgo leaf tablets contributes to reducing oxidative
stress, which plays an important role in DR. Previously, in their randomised double-blind
placebo-controlled study with 140 patients that lasted 3 three years, Zhao et al.
[92 ] showed that administering ginkgo leaf tablets with Liuwei Dihuang pills can reduce
the risk of DR and its prevalence by 66% (25% from the control group vs. 8.5% from
the treatment group). Zhao et al. [93 ] conducted a study by performing blood testing among diabetic patients to conclude
that GBEs lower the apoptosis rate of retinal vascular endothelial cells. Other research
works done in rats [89 ] link GBEs with the prevention of an increase in VEGF and TFN-α , proinflammatory mediators. In other diabetic animal models, GBEs have been seen
to reduce NO-induced oxidative stress, besides decreasing its production. This attenuates
the apoptosis of retinal ganglion cells and photoreceptor cells. GBEs have anti-inflammatory
effects, and one of the possible mechanisms is the ability to downregulate the expression
of PAF. GBEs can also significantly reduce the transcriptional expressions of hypoxia
inducible factor, HIF-1α , and VEGF in retinal pigment epithelial cells under hypoxic conditions [88 ]. Interleukin regulation appears to play a key role in the anti-inflammatory effect
of GBEs [94 ]. According to their background, GBEs improve retinal health by increasing the retinal
capillary blood flow in patients with DR. Correct GBE use lowers the incidence and
progression of this sight-threatening complication in diabetic patients. GBEs could
be potential candidates for use in the prevention and treatment of DR.
Glaucoma
Glaucoma can be defined as a series of ocular diseases characterised by a progressive
reduction of the visual field due to secondary optic nerve damage. It is mainly a
consequence of IOP that causes optic nerve injuries, starting with retinal ganglion
cell apoptosis [74 ]. This disease causes progressive and irreversible damage, and it remains asymptomatic
and is not usually detected until it is severe and has progressed to advanced stages.
Glaucoma is a leading cause of vision loss in people aged 60 years and more. However,
it can be prevented if treatment begins in the early disease stages [95 ]. There are several types of glaucoma, the most common of which is POAG. Among other
causes, it is provoked by the slow clogging of drainage canals, which raises intraocular
pressure. Glaucoma is linked to changes in NO metabolism, oxidative damage, and vascular
disorders. The main POAG-related damage is believed to be the degeneration of the
sclerocorneal TM. Several studies report a reduced field of vision and increased IOP
associated with the oxidative damage of TM cellsʼ DNA in the patientsʼ glaucoma, plus
an imbalance in the redox status being related to the high expression of endothelial-leukocyte
adhesion molecules in TM [50 ]. Nitrosative stress, together with oxidative stress caused by ROS of endogenous
and exogenous sources, can induce cell damage and death and, accordingly, ophthalmic
diseases [42 ], [50 ], [96 ]. Current glaucoma treatments are based mainly on the arrest of disease progression,
but they do not restore vision loss [97 ]. Previous studies report that several antioxidants, such as vitamins C and E, omega-3
and omega-6 fatty acids, and GBEs, can help to regulate IOP and protect the retina
from oxidative or nitrosative stress [96 ]. However, further research is needed to find new and more effective therapies to
prevent the irreversible blindness caused by glaucoma. Ginkgo scientific research
began due to the great interest that the antioxidant and neuroprotective properties
of ginkgo generated, which can be used against glaucoma. Thus, GBEs have demonstrated
that they play an important role in the improvement of several degenerative eye diseases,
including glaucoma. GBEs can improve the vision of patients with NTG and other ophthalmic
vascular diseases [98 ]. These beneficial effects can be explained by antioxidant and vascular protector
properties, which result in improved ocular blood flow after being administered. Despite
extensive information, more studies are needed to provide conclusive evidence [99 ]. Terpenes and flavonoids are the main compounds responsible for the antioxidant
ability of GBEs used against glaucoma [100 ]. In conclusion regarding GBEs and glaucoma, based on their background, GBE as a
neuroprotector can prevent retinal ganglion cell damage. These extracts can also be
used to prevent and treat other retinal neurodegenerative diseases. The use of GBEs
is proposed to improve oxidative stress in NTG patients and to increase visual acuity,
but further studies are needed.
Ischaemic Retinal Disease
Ischaemic Retinal Disease
Ischaemic retinopathy is a pathological state caused by the partial or total suppression
of ocular blood supply. It is a common cause of visual impairment, and sometimes blindness.
The dysregulation of ocular vessels can also contribute to the progression of ocular
diseases like glaucoma (vascular theory of glaucoma pathogenesis) [101 ]. Ischaemic retinopathy has been related to atherosclerotic disease by causing obstruction
of vessels (carotid artery occlusive disease), central retinal artery occlusion, or
branch retinal artery occlusion, retinal vein occlusion, diabetes, etc. Its consequences
can determine neurotoxic effects due to the sensitivity of retinal cells to ischaemic
injury. Compensation mechanisms are initiated by forming new abnormal blood vessels
in the retina. As a result, retinal ischaemia can lead to morphological and functional
changes, and produces pain and visual loss, depending on the part of the retina that
is affected [13 ]. In cellular terms, neuronal depolarisation increases intracellular calcium concentrations,
and oxidative stress is produced as a consequence of the lack of blood flow-dependent
energy. Glutamatergic stimulation may also increase. However, given the retinaʼs special
characteristics, it is more resistant to the damage induced by reduced blood flow
than the brain. Animal models have been used to study retinal ischaemia, and different
treatments have been proposed to avoid it [102 ]. In regards to natural products, very few studies on ginkgo and retinal ischaemia
have been reported [103 ], [104 ], [105 ], [106 ], [107 ], [108 ]. In vitro and in vivo experiments show the ability of ginkgo, its extracts, and its components to improve
blood flow in different vascular territories, and to prevent oxidative damage induced
at the cellular level [109 ], [110 ]. Ginkgo properties as a vasodilator and a free radical scavenger have been confirmed,
as have its activities as a membrane stabiliser and a regulator of metabolism ([Fig. 1 ]). The EGb761 extract is able to act as a NO scavenger by further inhibiting iNOS
mRNA expression [111 ]. Moreover, the effects on mechanisms of angiogenesis have been tested [15 ]. Some clinical trials performed with EGb761 indicate an effect of increasing ocular
blood flow in glaucoma patients with an improved visual field [112 ], [113 ]. Among its components, flavonoids can be partially responsible for this activity.
These phenolic compounds can also counteract the negative effects caused by ischaemic-dependent
oxidative stress to the extent that they are effective as free radical scavengers
and are able to inhibit lipid peroxidation [109 ], [114 ]. Studies into structure-activity relations performed with flavonoids show a positive
relationship between the presence of three free hydroxyl (OH) phenolic groups and
increased ocular blood flow in rabbit eyes [115 ]. In healthy subjects, EGb761 administration significantly improves ocular blood
flow [112 ]. The vasodilatory activity mediated by the release of the relaxing factors of the
vascular endothelium and prostacyclin (PGI2) due to the presence of flavonoids, and
the antiplatelet activity mediated by diterpenes, might justify these effects. Vascular
ocular alterations may be linked to NTG development. Park et al. [116 ] studied the effects of EGb761 on 30 NTG patients with a randomised, double-masked,
placebo-controlled clinical trial. The case group included 15 patients treated orally
with 80 mg of ginkgo extract, the equivalent to 19.2 mg of flavonoids, twice daily
for 4 weeks. The control group patients (N:15) received a placebo. After treatment
with EGb761, a statistically significant increase in peripapillary blood flow was
recorded. Volume and velocity also significantly increased. No side effects were recorded
in any patient. In the few patients recruited, the trial duration and variations in
the vascular effects depending on specific retinal territories were the main limitations
of this study. The effects of GBEs on the biomarkers of ocular perfusion in patients
with open-angle glaucoma have also been evaluated. Wimpissinger et al. [117 ] found no effects on retinal blood flow in healthy subjects (N:15) in a randomised,
double-masked, placebo-controlled, two-way crossover study after a single-dose treatment
(240 mg of the EGb761 extract corresponding to 57.6 mg of flavonoids and 14.4 mg of
terpenlactones). In a randomised, double blinded, placebo-controlled crossover study
(N:45), the effects on blood flow of a complex preparation containing ginkgo and other
antioxidant substances (vitamins, minerals, omega-3 from fish oil, PUFAs, N -acetylcysteine, bilberry fruit extract, coenzyme Q10, grape seed extract, quercetin,
flax seed oil, etc.) in patients with open-angle glaucoma were tested [118 ]. One month after treatment, a statistically significant increase in blood flow velocities
in all the retrobulbar blood vessels was observed as compared to the placebo. Superior
and inferior retinal capillary mean blood flows also increased. The patients treated
with the complex combination showed reduced vascular resistance in the central retinal
and nasal short posterior ciliary arteries versus the placebo group. The high composition
complexity of the employed preparation limited the direct relationship between the
ginkgo extract and the observed beneficial effects on retinal blood flow.
Fig. 1 Mechanisms of action of ginkgo in ischaemic retinal disease. Based on the article
of Osborne et al. [13 ].
Retinal Disease Produced by Light Oxidation
Retinal Disease Produced by Light Oxidation
Light has a phototoxic effect on ocular tissues, and, more specifically, on the retina.
Retinal damage depends on light intensity, its wavelength, and exposure time. While
acute exposure damage causes eyelid burns, photokeratitis, and solar retinopathy,
different epidemiological studies have found an association between long-term sun
exposure and cataracts, ARMD (the leading cause of vision loss in the Western world
in people aged 65 and over), climatic droplet keratopathy, and pterygium [119 ]. The retina and RPE are tissues exposed to high photo-oxidative stress levels due
to raised concentrations of available oxygen, and also to the presence of a number
of endogenous photosensitisers, such as vitamin A derivatives, lipofuscin, melanin,
flavins, and porphyrins. The outer retina contains high concentrations of polyunsaturated
fatty acids, including the most unsaturated fatty acid in the human body, docosahexaenoic
acid with six double bonds, which are extremely susceptible to peroxidation. Light
exposure increases photoreceptor degeneration and diminishes the cell density of certain
retinal layers (inner and outer nuclear layers and the ganglion cell layer). This
cell loss occurs by the apoptosis mediated by alterations in gene expression [120 ]. Photochemical damage to the retina can be classified as different types ([Fig. 2 ]) [121 ]. A photosensitive derivative of visual pigment N -retinylidene-N -retinylethanolamine ([Fig. 3 ]) may be involved in this phototoxicity. Many studies have demonstrated that antioxidant
compounds are able to prevent light-induced retinal damage. Among other natural antioxidants,
EGb 761 stands out. In vitro studies have shown the EGb761 effect on some important protein expression levels,
such as cathepsin B, heat shock protein, and cytochrome c reductase, and have pointed
out that multiple pathways can be involved in light-induced damage and the extract
protective effect [37 ]. Daily oral EGb 761 administration partially inhibits the apoptosis of photoreceptor
cells, which results in increased photoreceptor cell survival. This extract also preserves
retinal morphometry and provides functional protection [122 ]. Flavonoid glycosides are the main compounds responsible for the antioxidant capacity
of the ginkgo extract ([Fig. 4 ]). These compounds are able to scavenge O2 radicals, hydroxyl radicals, lipid peroxides, and iron ions [119 ]. In addition to ginkgo flavons, the extract also contains other substances of less
interest, such as organic acids. Thus, EGb 761 possesses both hydrophilic and lipophilic
characteristics, unlike other antioxidants such as ascorbic acid, glutathione, and
uric acid. Intraperitoneal EGb 761 administration (100 mg/kg) lasting between 1 week
before and 2 weeks after light exposure increases retinal antioxidant capacity and
can partially inhibit photoreceptors apoptosis [123 ]. Grosche et al. [124 ] demonstrated that EGb 761 administration does not prevent Müller cell hypertrophy,
but inhibits the expression of pathological marker molecules.
Fig. 2 Types of light-induced damage to the retina. Based on the article of Boulton et al.
[121 ].
Fig. 3 N -retinylidene-N -retinylethanolamine.
Fig. 4 EGb 761 main flavonoids.
Others
GBEs can be used in processes that are the primary cause of the aforementioned retina
pathologies, or are secondary causes that lead to disease development. In this context,
EGb 761 can prevent retinal pigmented epithelial degeneration because it is a scavenger
of NO and potentially protects RPE cells from its antiproliferative action [11 ]. The same extract also has a positive effect on inflammatory ritinitis according
to an experimental model of autoimmune uveoretinitis induced in rats [125 ]. Some studies demonstrate that ginkgo can be useful for treating BD, which is a
multisystem disorder, including ophthalmic manifestations such as iritis or uveitis.
BD is linked to oxidative processes. For this reason, the use of pharmacological agents
with antioxidant properties is considered increasingly important. Indeed, EGb 761
is one of the proposed pharmacological agents because it is a free radical scavenger
and its use strengthens the organismʼs antioxidant defence system and greatly contributes
to the clinical improvement in BD [126 ]. Other authors have also investigated the EGb 761 effect on uveitis using animal
models. They concluded that the ginkgo extract decreases the uveitis anti-inflammatory
process, but also notably suggest the need for more research about EGb 761 properties
and effects to gain a better understanding of the mechanism and to confirm activities
like blocking iNOS protein expression and the anti-inflammatory effect on eyes [127 ], [128 ].
RP is another retina disease related to oxidative processes. This disorder leads to
reduced vision and particularly affects night vision, and can lead to blindness in
severe cases because of alterations that the retinal rod and cone cells undergo. GBEs
act on preventing the loss of retinal ganglion cells and optic nerve atrophy by protecting
the optic nerve from degeneration. Thus, these extracts may prevent blindness in patients
with RP. Other studies suggest that GBEs conserve mitochondrial metabolism and ATP
production in tissues by inhibiting morphological distortion and oxidative damage
from mitochondrial aging. Others have demonstrated the ability of GBEs for scavenging
NO and, hence, their protector effect against NO reactivity [74 ].
Future Perspectives and Conclusions
Future Perspectives and Conclusions
Retinal diseases are related to oxidative stress, and flavonoids, terpenes, and other
antioxidant components of ginkgo extracts play a particular important role in their
treatment and prevention. Together with antioxidant properties, anti-inflammatory
activities are also of interest. These ginkgo extract capacities can be attributed
to the synergistic activity of different extract components [129 ]. Two mechanisms of action have been suggested in order to explain GBEs antioxidant
capacity. Components of the extracts are able to scavenge different free radicals,
including ROS, such as hydroxyl radicals (OH·) [130 ], superoxide radicals (O2
− ), peroxyl radicals (ROO·), and hydrogen peroxide (H2 O2 ), among others, and also reactive nitrogen species, such as nitric oxide (NO·) and
ferryl ion species [131 ]. This activity is mainly related to flavonoids, while terpenes increase cell enzymatic
antioxidant mechanisms. Bilobalide and ginkgolides increase superoxide dismutase,
glutathione peroxidase, catalase, and heme-oxigenase-1 activities, which promotes
GBEs antioxidant effect [132 ]. In addition, it has been reported that EGb 761 is able to regulate Mn and Cu homeostasis
in the brain, metals that act as cofactors of antioxidant enzymes [133 ], [134 ]. The NO scavenging capacity of GBEs can inhibit iNOS expression. In this sense,
the inhibition of NF-κ B mediated by GBEs should contribute to the downregulation of iNOS and other inflammatory
mediators such as TNF-α , IL-6, IL-2, IL-8, and ICAM-1, corroborating ginkgoʼs dual role as an antioxidant
and anti-inflammatory agent [135 ]. The abundant PUFAs in the retina could be protected against peroxidation by ginkgo
extracts, as has been previously demonstrated in rat liver microsomes [136 ]. Drieu et al. [137 ] reported that EGb 761 produces an increase in circulating and cellular PUFA amounts,
including arachidonic, docosahexaenoic acids, and eicosapentaenoic acid. This effect
should be mediated acting on the synthesis and/or catabolism of PUFAs. These results
pointed out that in addition to the antioxidant capacity of ginkgo components, the
increase in PUFAs can explain a most durable effect of EGb 761. PUFAs may be the target
of oxidative damage, preserving other important molecules. On the other hand, ginkgo
extract avoids peroxidation of membrane PUFAs, preserving membrane fluidity and keeping
their integrity. Furthermore, docosahexaenoic acid, which was increased twofold in
rats after EGb 761 treatment, plays an essential role in visual function, regulating
via rhodopsin the photo-signal transduction, and protecting RPE from oxidative stress
[138 ].
GBEs have been used for the treatment of cerebral and peripheral vascular insufficiency
due to their vasorelaxant properties [139 ] as well as their capacity to regenerate an injured peripheral nervous system [140 ]. An increase in angiogenesis has been reported by Zhu et al. [141 ] as a consequence of VEGF, with a significant rise in rats treated with EGb 761 after
acellular nerve allografts. GBEs have also shown, in a rat model, a promotion of VEGF
expression in ischaemic brain tissue after a subarachinoid haemorrhage [142 ]. However, there are contradictory results regarding a ginkgo effect over this growth
factor. Oh et al. [143 ] reported that GBEs reduce hypoxia-inducible factor-1α and VEGF expression in cultured RPE cells under chemical hypoxia. Juárez et al. [144 ] found similar results in a murine model. The vasodilating properties of GBEs make
choroidal circulation have large-calibre vessels and a high flow rate, providing cells
more oxygen and attenuating some retinal diseases in a noninvasive way. However, more
studies are needed in order to clarify inconsistent data before GBEs can be used as
a therapeutic agent in diseases such as macular degeneration.
The experimental and clinical data obtained to date indicate that gingko leaf extract
is well tolerated and is apparently safe for humans. Most studies demonstrate its
potential therapeutic role and its efficacy in degenerative diseases of the retina,
such as AMD, DR, glaucoma, ischaemic retinal disease, retinal diseases produced by
light oxidation, and RD. The specific mechanism by which GBEs induce effects is still
to be fully elucidated. Nevertheless, beneficial gingko effects can be explained by
its antioxidant, anti-inflammatory, and vascular protector properties. In conclusion,
GBEs could be an effective phytochemical therapeutic target, but further studies are
necessary.
Authorsʼ Contributions
All authors contributed to the design of the study, the selection of the retinal diseases,
the establishment of the inclusion and exclusion criteria, the background selection,
and the approach of our review study. All authors have assessed all comments and criticisms
to write and review the article. Each author was responsible for a specific section.
Isabel Martínez-Solís and Francisco Bosch-Morell together investigated the background
of G. biloba use in cases of several retinal diseases such as Behcetʼs disease and retinitis pigmentosa.
Nuria Acero was mainly responsible for the introduction and discussion sections. Encarna
Castillo was mainly responsible for the section on ginkgo use when the retinal disease
was produced by light oxidation. María Eugenia González-Rosende was mainly responsible
for the section on ginkgo use in the event of ARMD. Dolores Muñoz-Mingarro was responsible
for the section linked to the use of ginkgo for retinal detachment. Teresa Ortega
investigated the use of G. biloba in patients that suffered from ischaemic retinal disease. María Amparo Sanahuja was
responsible for the section related to the use of ginkgo for glaucoma. Finally, Victoria
Villagrasa investigated ginkgo and diabetic retinopathy. The work was coordinated
by Isabel Martínez-Solís.
